This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gadsby, R. Search for Related Content Social Bookmarking                         What's this?

Using insulin earlier in the treatment of type 2 diabetes

Centre for Primary Healthcare Studies, Warwick University, Coventry, CV4 7AL, UK, Roger.Gadsby{at}warwick.ac.uk

Type 2 diabetes is a progressive disease. Initial management with diet and exercise is fundamental. However, even if concordance is good, many will go on to require oral agent therapy to control hyperglycaemia. Initial metformin monotherapy and then oral combination therapy may be required as the disease progresses. When combinations of oral agents are insufficient to achieve good glycaemic control insulin therapy will be required. Various combinations of insulin and oral agents can be used to reduce the complications of hypoglycaemia and weight gain associated with insulin treatment. Simple regimes, using once-daily long-acting insulin analogues combined with oral metformin would seem to offer the possibility of good glycaemic control with minimal weight gain and hypoglycaemia.

Key Words: type 2 diabetes • oral agents • insulin • hypoglycaemia • basal insulin • glycaemic control.

References

• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33) Lancet 1998;352:837-53.[CrossRef]
• Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
• UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ukpds Group. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58.[Abstract]
• Johnson JL, Wolf SL, Kabadi UM Efficiency of insulin and sulphonylurea combination therapy in type 2 diabetes: a meta-analysis of the randomised placebo controlled trials. Arch Intern Med 1996;156:259-64.[Abstract/Free Full Text]
• Riddle MC Timely addition of insulin to oral therapy for type 2 diabetes - editorial. Diabetes Care 2002;25:395-6.[Free Full Text]
• Buse J. Combining Insulin and oral agents. Am J Med 2000;108:23S-32S.[CrossRef][Medline] [Order article via Infotrieve]
• Kelley DE, Bidcot P., Freedman Z. et al. Efficacy and safety of acarbose in insulin treated patients with type 2 diabetes. Diabetes Care 1998;21: 2056-61.[Abstract]
• Schwatz S., Rankin P., Fonseca V., Graveline JF for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin treated patients with type 2 diabetes. N Engl J Med 1998;338:861-6.[Abstract/Free Full Text]
• Rubin C., Egan J., Schneider R. Pioglitazone 014 Study Group. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes (abstract). Diabetes 1999;48(suppl 1):A110(abstract 0474).
• Raskin P., Dole JF, Rappaport E. Rosiglitazone improves glycaemic control in poorly controlled insulin treated type 2 diabetes (abstract). Diabetes 1999;48(suppl 1):A94(abstract 0404).[CrossRef]
• Landstedt-Hallin L., Adamson U., Arner P., Bolinder J., Lins P-E. Comparison of bedtime NPH or prandial regular insulin combined with glibenclamide in secondary sulphonylurea failure. Diabetes Care 1995;18:1183-6.[Abstract]
• Bastyr EJ, Johnson ME, Trautmann ME, Anderson JHJ, Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes after oral agent failure. Clin Ther 1999;21:1703-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Owens DR, Coates PA, Luzio SD, Tinberew JP, Kurzhals RK Phamacokinetics of 125 I - labelled insulin glargine (HOE 901) in healthy men. Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-19.[Abstract/Free Full Text]
• Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.[Free Full Text]
• Yki-Jarvinen H., Dressler A., Zieman M. Less nocturnal hypoglycaemia and better post dinner glucose control with bedtime insulin glargine compared to bedtime NPH insulin during insulin combination therapy in type 2 diabetes HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.[Abstract/Free Full Text]
• Witthaus E., Stewart J., Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001;18:619-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 2, 119-122 (2003)
DOI: 10.1177/14746514030030020701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gadsby, R. Search for Related Content Social Bookmarking                         What's this?